Stargardt Disease

Sponsor – IVERIC BIO (Open to Enrollment)

Study: OPH2005
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease
https://clinicaltrials.gov/ct2/show/NCT03364153?term=Phase+2b+Stargardt&draw=2&rank=1